West Pharmaceutical (NYSE: WST) inks 10-year Daikyo licensing, distribution deal
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
West Pharmaceutical Services, Inc. entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd., effective July 14, 2026. The company holds a 49% ownership interest in Daikyo.
The Crosslicense Agreement provides mutual sharing of know-how and cooperation in developing closures, vials, cartridges, syringes and related pharmaceutical packaging and delivery components. Each party may license the other’s know-how, patents and trademarks; Daikyo’s license from West is non-exclusive, while West’s license from Daikyo is exclusive outside Japan, in each case subject to limited exceptions. The arrangement is royalty-free except for a fixed royalty rate on certain patents and non-patented technical information. One Distributorship Agreement grants West exclusive rights to distribute Daikyo products outside Japan, and the other grants Daikyo non-exclusive rights to distribute West products in Japan. Each agreement has a 10-year term and may be terminated earlier under specified circumstances, including mutual consent or a change in control.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Ownership interest in Daikyo: 49%
Agreement term: 10-year term
Effective date of Agreements: July 14, 2026
+4 more
7 metrics
Ownership interest in Daikyo
49%
West Pharmaceutical Services maintains a 49% ownership interest in Daikyo Seiko, Ltd.
Agreement term
10-year term
Each of the Crosslicense and Distributorship Agreements has a 10-year term.
Effective date of Agreements
July 14, 2026
The Crosslicense and Distributorship Agreements are effective July 14, 2026.
Prior agreement date
January 18, 2017
The new Agreements are substantially similar to agreements dated January 18, 2017.
Letter Agreement date
July 2, 2018
The earlier arrangements were amended by a Letter Agreement dated July 2, 2018.
Amendment Agreement date
October 15, 2019
The earlier arrangements were also amended by an Agreement dated October 15, 2019.
Quarter for exhibit filing
Quarter ending September 30, 2026
Redacted copies of the Agreements will be filed with the Form 10-Q for the quarter ending September 30, 2026.
Key Terms
Material Definitive Agreement, Crosslicense Agreement, Distributorship Agreements, royalty-free, +1 more
5 terms
Material Definitive Agreement regulatory
"Item 1.01 Entry Into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
Crosslicense Agreement regulatory
"Amended and Restated Technology Exchange and Crosslicense Agreement (the “Crosslicense Agreement”)."
Distributorship Agreements regulatory
"two Distributorship Agreements (the “Distributorship Agreements”) effective July 14, 2026."
Distributorship agreements are contracts where a maker of goods grants another company the right to sell and distribute those products in a specific area or market. They matter to investors because they determine how widely products reach customers, how revenue and costs are shared, and who handles marketing, inventory and returns—similar to leasing a storefront and agreeing who pays for stock and sales work. These terms directly affect a company’s sales growth, profit margins and legal or renewal risks.
royalty-free financial
"The Crosslicense Agreement is royalty-free except for a fixed royalty rate."
change in control regulatory
"may be terminated... including... mutual written consent or in the event of a change in control."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
FAQ
What new agreements did West Pharmaceutical Services (WST) enter into with Daikyo Seiko, Ltd.?
West Pharmaceutical Services entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements with Daikyo Seiko, Ltd.. These cover technology sharing, cross-licensing of patents and trademarks, and product distribution between the parties across Japan and the rest of the world.
When do the new West Pharmaceutical (WST) and Daikyo agreements become effective and how long do they last?
The new agreements between West Pharmaceutical and Daikyo are effective July 14, 2026 and each has a 10-year term. They can be terminated earlier under defined circumstances, including mutual written consent or a change in control of either party.
What is West Pharmaceutical’s ownership interest in Daikyo Seiko, Ltd. (WST)?
West Pharmaceutical Services maintains a 49% ownership interest in Daikyo Seiko, Ltd. This equity stake exists alongside the technology exchange and distribution arrangements, aligning West’s financial and strategic interests with Daikyo’s performance and collaboration.
How are distribution rights structured between West Pharmaceutical (WST) and Daikyo under the new agreements?
One Distributorship Agreement makes West the exclusive distributor of Daikyo products in all countries other than Japan, subject to limited exceptions. The other appoints Daikyo as a non-exclusive distributor of West products in Japan, with otherwise substantially similar terms.
Are royalties payable under the West Pharmaceutical–Daikyo Crosslicense Agreement?
The Crosslicense Agreement is generally royalty-free, but includes a fixed royalty rate applicable to licensing certain patents and non-patented technical information. This structure governs compensation when specified intellectual property or technical know-how is licensed between the companies.
Under what conditions can the West Pharmaceutical (WST) and Daikyo agreements be terminated early?
Each agreement may be terminated before its 10-year term expires under defined conditions, including mutual written consent or a change in control of either party. If the Crosslicense Agreement ends, the parties will negotiate continued use of know-how, trademarks and licensed patents.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – July 14, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: 610 -594-2900
Not Applicable | ||
(Former name or address, if changed since last report.) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 1.01 Entry Into a Material Definitive Agreement.
West Pharmaceutical Services, Inc. (the "Company") and Daikyo Seiko, Ltd. ("Daikyo") have entered into an Amended and Restated Technology Exchange and Crosslicense Agreement (the “Crosslicense Agreement”) as well as two Distributorship Agreements (the “Distributorship Agreements”) effective July 14, 2026 (the “Agreements”). The Company maintains a 49% ownership interest in Daikyo.
The terms of the Agreements are substantially similar to the terms of the Amended and Restated Technology Exchange and Crosslicense Agreement dated January 18, 2017 and the two Distributorship Agreements dated January 18, 2017 between the parties, as amended by the Letter Agreement dated July 2, 2018 and the Amendment Agreement dated October 15, 2019.
Under the Crosslicense Agreement, each party has agreed to share with the other its know-how relating to, and to cooperate in the joint development of, closures, vials, cartridges, syringes, medical device components and similar products used in connection with the packaging, delivery, administration or dispensing of pharmaceutical products. The Crosslicense Agreement permits each party to license the other’s know-how, patents and trademarks in the manufacture, use and sale of those products. Daikyo’s license from West is non-exclusive and West’s license from Daikyo is exclusive outside of Japan subject to certain limited exceptions. The Crosslicense Agreement is royalty-free except for a fixed royalty rate that is generally applicable to the licensing of certain patents and non-patented technical information.
One Distributorship Agreement authorizes the Company as the exclusive distributor of Daikyo products in all countries other than Japan, subject to certain limited exceptions. The other Distributorship Agreement authorizes Daikyo as a non-exclusive distributor of Company products in Japan. Both Distributorship Agreements are otherwise substantially similar in material terms and conditions.
Each of the Agreements has a 10-year term. Each Agreement may be terminated before its respective term expires under certain circumstances, including, but not limited to, mutual written consent or in the event of a change in control of either party. If the Crosslicense Agreement is terminated, the parties have agreed to negotiate within a specified period the terms under which they may continue to use the know-how and trademarks and to make, use or sell products under licensed patents.
The foregoing descriptions of each of the Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of each of the Agreements, redacted copies of which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q for the quarter ending on September 30, 2026.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibit No. | Description | ||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 14, 2026 | WEST PHARMACEUTICAL SERVICES, INC. | ||||
| By: | /s/ Norman D. Finch Jr. | ||||
| Norman D. Finch Jr. | |||||
Senior Vice President, General Counsel and Corporate Secretary | |||||
3
EXHIBIT INDEX
Exhibit No. | Description | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
4